Marijuana: What We Should All Know Elinore F. McCance-Katz, MD, PhD - - PowerPoint PPT Presentation

marijuana what we should all know
SMART_READER_LITE
LIVE PREVIEW

Marijuana: What We Should All Know Elinore F. McCance-Katz, MD, PhD - - PowerPoint PPT Presentation

Marijuana: What We Should All Know Elinore F. McCance-Katz, MD, PhD Assistant Secretary for Mental Health and Substance Use Substance Abuse and Mental Health Services Administration U.S. Department of Health and Human Services Smart Approaches


slide-1
SLIDE 1

1

Marijuana: What We Should All Know

Elinore F. McCance-Katz, MD, PhD Assistant Secretary for Mental Health and Substance Use Substance Abuse and Mental Health Services Administration U.S. Department of Health and Human Services

Smart Approaches to Marijuana April 25, 2019

slide-2
SLIDE 2

2

The Issue

Marijuana is rapidly becoming more widely available in the U.S.: 33 states: allow medical marijuana use; 10 states plus DC have legalized recreational use Huge and profitable industry that markets heavily with health claims that have little to no basis and which have had virtually no counter arguments put forward until the present time Numerous forms: smoked, edibles, oil for vaping, lotions, transdermal patches

slide-3
SLIDE 3

3

Marijuana: The Issue

  • Increase in THC content over time led to higher potency intoxicant:
  • THC content: 4% (1990s) increased to 12% (2014)
  • Current average MJ extract has THC levels at > 50%
  • THC: component responsible for euphoria/intoxication
  • Can also produce anxiety, agitation, paranoia, and psychosis
  • Addiction liability: 10-20% of users will develop use disorder (Volkow et al. 2016)
  • Declining CBD content in currently available MJ
  • Not thought to be addictive; May reduce psychosis
  • Medical value: FDA approved for certain seizure disorders
  • CBD content in marijuana dropped by approx. 50% from 1990s to 2014
  • THC content increased
  • THC/CBD ratio 1995: 14; 2014: 80

(Ehsoly MA et al. 2016)

slide-4
SLIDE 4

4

Risks and Adverse Outcomes

  • Downplayed by industry; ignored by states
  • Low birth weight
  • Pulmonary symptoms
  • MVAs
  • Cognitive impairment
  • Poor performance in school and at work
  • Addiction
  • Risk of adverse outcomes to our children and young adults
slide-5
SLIDE 5

5

State Effective Date 2012-13 Percentages 2012-13 Numbers 2013-14 Percentages 2013-14 Numbers 2014-15 Percentages 2014-15 Numbers 2015-16 Percentages 2015-16 Numbers Alabama N/A 9.69% 389 9.98% 404 9.60% 389 9.50% 386 Georgia N/A 11.44% 925 11.75% 963 12.67% 1,052 12.46% 1,048 Idaho N/A 9.82% 127 11.58% 152 11.40% 152 11.62% 158 Indiana N/A 11.05% 598 12.86% 700 13.88% 760 13.35% 733 Iowa N/A 10.40% 266 9.74% 251 9.05% 235 9.75% 254 Kansas N/A 8.21% 192 11.01% 259 12.38% 292 11.17% 265 Kentucky N/A 9.22% 334 10.93% 398 12.28% 449 12.79% 470 Louisiana N/A 10.76% 405 11.23% 425 11.22% 427 11.22% 429 Mississippi N/A 8.78% 213 9.40% 229 8.67% 212 9.46% 231 Missouri N/A 11.64% 581 12.73% 639 13.53% 683 13.19% 668 Nebraska N/A 9.98% 152 10.35% 158 10.75% 166 11.33% 176 North Carolina N/A 10.88% 877 12.07% 986 11.79% 975 11.90% 996 North Dakota N/A 9.92% 58 10.25% 62 9.90% 61 9.80% 61 Oklahoma N/A 9.97% 310 10.75% 338 11.28% 358 11.18% 357 South Carolina N/A 11.72% 460 11.55% 460 12.56% 507 10.92% 448 South Dakota N/A 9.64% 66 8.97% 62 10.77% 75 11.85% 83 Tennessee N/A 9.93% 535 10.29% 560 11.05% 606 12.82% 709 Texas N/A 9.38% 1,972 9.52% 2,043 10.10% 2,213 10.14% 2,264 Utah N/A 8.76% 196 9.84% 224 9.07% 211 9.62% 229 Virginia N/A 12.39% 839 13.04% 891 11.54% 796 11.06% 768 West Virginia N/A 10.12% 159 10.93% 172 11.07% 174 11.45% 179 Wisconsin N/A 11.12% 534 11.86% 572 12.05% 584 12.18% 592 Wyoming N/A 10.11% 48 10.72% 51 10.87% 52 10.62% 51

What Happens as State Laws Liberalize?

Past Year Marijuana Use among Persons Aged 12 or Older Residing in States with No Legalization of Marijuana

Range: 9-13%

Percentages and Estimated Numbers (in Thousands), Annual Averages Based on 2012-2013, 2013-2014, 2014-2015, and 2015-2016 NSDUHs

slide-6
SLIDE 6

6

State Effective Date 2012-13 Percentages 2012-13 Numbers 2013-14 Percentages 2013-14 Numbers 2014-15 Percentages 2014-15 Numbers 2015-16 Percentages 2015-16 Numbers Arizona Nov 2, 2010 12.94% 699 13.69% 752 13.12% 734 12.22% 696 Arkansas Nov 9, 2016 9.69% 235 11.37% 277 11.59% 284 11.14% 274 Connecticut Oct 1, 2012 14.00% 425 14.00% 427 15.67% 479 15.08% 461 Delaware Jul 1, 2011 13.97% 108 13.98% 109 13.06% 103 13.18% 105 Florida Jan 3, 2017 11.43% 1,885 11.87% 1,990 12.59% 2,152 13.07% 2,275 Hawaii Dec 28, 2000 13.37% 151 12.58% 144 12.72% 147 13.05% 151 Illinois Jan 1, 2014 11.66% 1,247 12.16% 1,305 12.47% 1,339 12.31% 1,320 Maryland Jun 1, 2014 11.47% 565 13.48% 670 15.13% 757 15.50% 779 Michigan Dec 4, 2008 15.22% 1,268 15.60% 1,304 15.10% 1,266 15.68% 1,317 Minnesota May 30, 2014 11.93% 536 12.22% 553 12.69% 579 12.91% 592 Montana Nov 2, 2004 15.78% 134 14.07% 120 15.38% 133 18.41% 160 New Hampshire Jul 23, 2013 15.39% 175 16.95% 194 17.35% 199 17.58% 202 New Jersey Jul 1, 2010 10.18% 759 11.25% 844 11.86% 894 12.01% 907 New Mexico Jul 1, 2007 15.09% 257 15.61% 267 14.72% 253 15.83% 272 New York Jul 5, 2014 14.13% 2,342 14.24% 2,372 15.04% 2,519 14.86% 2,491 Ohio Sep 8, 2016 12.81% 1,237 11.57% 1,122 12.13% 1,179 13.81% 1,344 Pennsylvania May 17, 2016 11.33% 1,223 11.70% 1,265 12.35% 1,339 13.05% 1,415 Rhode Island Jan 3, 2006 20.22% 181 18.95% 170 18.81% 170 20.31% 184 Vermont Jul 1, 2004 19.10% 104 19.97% 108 20.50% 111 21.79% 118

What Happens as State Laws Liberalize?

Past Year Marijuana Use among Persons Aged 12 or Older Residing in States with Legal Medical Marijuana Use Only

Range: 11-21.8%

Percentages and Estimated Numbers (in Thousands), Annual Averages Based on 2012-2013, 2013-2014, 2014-2015, and 2015-2016 NSDUHs

slide-7
SLIDE 7

7

State Effective Date 2012-13 Percentages 2012-13 Numbers 2013-14 Percentages 2013-14 Numbers 2014-15 Percentages 2014-15 Numbers 2015-16 Percentages 2015-16 Numbers Alaska Feb 24, 2015 19.69% 114 19.60% 114 21.92% 127 23.00% 134 California Nov 9, 2016 (revised penalties) 13.89% 4,384 14.49% 4,633 15.25% 4,936 16.23% 5,296 Colorado Dec 10, 2012 (revised penalties); Jan 1, 2014 (commercial sales) 18.92% 814 20.74% 909 23.09% 1,033 23.12% 1,057 District of Columbia Feb 26, 2015 21.02% 116 21.70% 121 23.51% 134 24.68% 143 Maine Jan 30, 2017 (grow and possess) 16.24% 186 19.55% 224 19.69% 227 19.81% 228 Massachusetts Dec 15, 2016 15.57% 885 17.23% 989 18.26% 1,058 18.64% 1,088 Nevada Jan 1, 2017 14.10% 324 13.01% 304 12.95% 309 13.13% 319 Oregon Mar 29, 2016 19.03% 630 19.39% 649 19.42% 659 22.70% 783 Washington Dec 6, 2012 17.48% 1,008 18.92% 1,105 17.49% 1,037 18.93% 1,140

What Happens as State Laws Liberalize?

Past Year Marijuana Use among Persons Aged 12 or Older Residing in States with Legal Medical and Recreational Marijuana Use

Range: 13-25%

Percentages and Estimated Numbers (in Thousands), Annual Averages Based on 2012-2013, 2013-2014, 2014-2015, and 2015-2016 NSDUHs

slide-8
SLIDE 8

8

Illicit Drug Use Impacts Millions: Marijuana Most Widely Used Drug

20.1 MILLION

People aged 12 or

  • lder had a

substance use disorder

0.3% 0.6% 0.6% 1.9% 2.2% 6.6% 15.0%

Heroin Methamphetamines Inhalants Hallucinogens Cocaine Psychotherapeutic Drugs Marijuana

40.9 MILLION 18.1 MILLION 5.9 MILLION 5.1 MILLION 1.6 MILLION 1.8 MILLION 886,000

0% 2% 4% 8% 12% 14% 10% 6% 16%

Prescription opioids, sedatives, tranquilizers, stimulants

PAST YEAR, 2017, 12+

slide-9
SLIDE 9

9

How did we get to where we are and what does the data tell us about ongoing risks?

slide-10
SLIDE 10

10

Adolescent Perceptions of Great Risk of Harm From Substance Use

See table 3.1 in the 2016 and 2017 NSDUH detailed tables for additional information.

PAST YEAR, 2015 - 2017, 12-17

+ Difference between this estimate and the 2017 estimate is statistically significant at the .05 level.

slide-11
SLIDE 11

11

Young Adult Perceptions of Great Risk of Harm From Substance Use

See table 3.1 in the 2016 and 2017 NSDUH detailed tables for additional information.

PAST YEAR, 2015 - 2017, 18-25

+ Difference between this estimate and the 2017 estimate is statistically significant at the .05 level.

slide-12
SLIDE 12

12

Past Year Initiates, Age Group & Substance

PAST YEAR, 2017, 12+

* Initiation of misuse

slide-13
SLIDE 13

13

  • Since 2007, past year

marijuana use has increased 37%

  • In 2016, 1 in 7

Americans ≥ 12 years used marijuana in the past year

  • Frequent marijuana use

(using ≥ 200 days in the past year) increased 37% since 2002

  • Nearly 1 in 3 people

using marijuana in 2016 reported using ≥ 200 days in the past year

5 10 15 20 25 30 35 Past Year Marijuana Use Use of Marijuana 200 Days or More in Past Year Among Those Reporting Past Year Marijauna Use Percent 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016

Source: Jones CM Analysis of the NSDUH 2002-2016 Public Use Files

Marijuana Use Is Increasing in the U.S.

slide-14
SLIDE 14

14

Marijuana Use by Age Group

PAST MONTH, 2015 - 2017, 12+

See figure 13 in the 2017 NSDUH Report for additional information. + Difference between this estimate and the 2017 estimate is statistically significant at the .05 level.

Significant Increases in Use

slide-15
SLIDE 15

15 + Difference between this

estimate and the 2017 estimate is statistically significant at the .05 level.

Marijuana Use among Young Adults

PAST MONTH, 2015 - 2017, 18 - 25

Special analysis of the 2017 NSDUH Report. + Difference between this estimate and the 2017 estimate is statistically significant at the .05 level.

slide-16
SLIDE 16

16 + Difference between this

estimate and the 2017 estimate is statistically significant at the .05 level.

Marijuana Use among Young Adults: Significant Increases in Women

PAST MONTH, 2015 - 2017, 18 - 25

Special analysis of the 2017 NSDUH Report. + Difference between this estimate and the 2017 estimate is statistically significant at the .05 level.

slide-17
SLIDE 17

17

Substance Use in Past Month Among Pregnant Women

Special analysis of the 2017 NSDUH Report. + Difference between this estimate and the 2017 estimate is statistically significant at the .05 level.

PAST MONTH, 2015 - 2017, 15 - 44

slide-18
SLIDE 18

18

Marijuana Use among Women by Pregnancy Status

Special analysis of the 2017 NSDUH Report. + Difference between this estimate and the 2017 estimate is statistically significant at the .05 level.

PAST MONTH, 2015 - 2017, 15 - 44

slide-19
SLIDE 19

19

Daily or Almost Daily Marijuana Use among Women by Pregnancy Status

PAST YEAR, 2015 - 2017, 15 - 44

Special analysis of the 2017 NSDUH Report. + Difference between this estimate and the 2017 estimate is statistically significant at the .05 level.

slide-20
SLIDE 20

20

Why is this Data Important? Marijuana use in Pregnancy may be associated with: Fetal growth restriction Stillbirth Preterm birth Neurological development issues in exposed children: Hyperactivity Cognitive deficits (Metz TD and Stickrath EH, 2015)

slide-21
SLIDE 21

21

Co-Occurring Disorders: Youth (12-17) Opioid Misuse, Heavy Alcohol Use, and Major Depressive Episode (MDE) by Marijuana Use Status

Special analysis of the 2017 NSDUH Report. + Difference between this estimate and the estimate youth with past year marijuana use is statistically significant at the .05 level.

PAST YEAR/MONTH, 2017, 12 - 17

slide-22
SLIDE 22

22

Co-Occurring Disorders: Young Adult (18-25) Opioid Misuse, Heavy Alcohol Use, and Major Depressive Episode by Marijuana Use Status

PAST YEAR/MONTH, 2017, 18 - 25

Special analysis of the 2017 NSDUH Report. + Difference between this estimate and the estimate with past year marijuana use is statistically significant at the .05 level.

slide-23
SLIDE 23

23

Co-Occurring Disorders: Adult (26 and older) Opioid Misuse, Heavy Alcohol Use, and Major Depressive Episode by Marijuana Use Status

PAST YEAR/MONTH, 2017, 26+

Special analysis of the 2017 NSDUH Report. + Difference between this estimate and the estimate with past year marijuana use is statistically significant at the .05 level.

slide-24
SLIDE 24

24

ALTERED BRAIN STRUCTURE AND FUNCTION IN YOUTH WHO REGULARLY USE MARIJUANA

Early (<18y) Marijuana Use Decreases Brain Fiber Connectivity Decreases in brain fiber connectivity may help explain the cognitive impairment and vulnerability to certain mental health conditions seen among people with early onset and regular use.

Source: Zalesky et al Brain 2012

slide-25
SLIDE 25

25

Average Point Difference in IQ Score (IQ at age 38 – IQ at age 13)

Intelligence:

PERSISTENT CANNABIS (MARIJUANA) USE DISORDER LINKED TO SIGNIFICANT IQ DROP BETWEEN CHILDHOOD AND MIDLIFE

Source: Meier MH et al., PNAS Early Edition 2012

¡ Followed 1,037 individuals from birth to age 38 ¡ Tested marijuana use and disorders at 18, 21, 26, 32 and 38 years of age ¡ Tested for IQ at ages 13 and 38

  • 8
  • 6
  • 4
  • 2

2 Never Used Marijuana Cannabis Dependence in 1 Study Wave Cannabis Dependence in 2 Study Waves Cannabis Dependence in 3 Study Waves

All groups started with roughly equivalent IQ scores at age 13 By age 38, those diagnosed with cannabis dependence in 3 study waves (the most persistent users of cannabis) had lost nearly 6 IQ points There was a consistent dose- response relationship across the groups

slide-26
SLIDE 26

26

26

Comparison of Alcohol and Marijuana on Adolescent Cognitive Development

Sample: 3826 seventh grade students from 31 schools (Montreal, Canada) Method: Assessed annually for 4 years: Alcohol and cannabis use Recall memory, Perceptual reasoning, Inhibitory control, Working memory Results: Cannabis (marijuana) use (but not alcohol use) showed significant negative effects on:

  • Working memory
  • Inhibitory control
  • Delayed recall memory
  • Perceptual reasoning
  • Increases in marijuana use frequency were associated with reductions in delayed memory

recall and perceptual reasoning with greater effects observed in those with earlier onset use

  • Marijuana effects were independent of alcohol effects and were more pronounced

than for alcohol

  • Lasting effects of adolescent marijuana use can be observed on important cognitive functions

Morin, JFG et al., 2019

slide-27
SLIDE 27

27

Marijuana Use: Link to Prescription Pain Medication (Opioid) Abuse Association of marijuana use with abuse of prescription pain medications and addiction

2.62 2.78

1 2 3 4 5

Risk of incident prescription

  • pioid misuse

Risk of incident prescription

  • pioid use disorder

Risk of subsequent prescription opioid misuse and use disorder was increased among people who reported marijuana use 5 years earlier

Data from National Epidemiologic Survey on Alcohol and Related Conditions Olfson et al., 2017

slide-28
SLIDE 28

28

28

Marijuana-Associated Psychosis

Source: Andréasson et al Lancet, 1987.

1 2 10 <50 >50

30 20 10

Number of times marijuana taken Cases per 1,000

4.5 1.6 1 2 3 4 5 6 7 8 9

Cannabis users by age 15 years Cannabis users by age 18 years

Odds ratio Risk of schizophrenia increases as marijuana use increases Higher risk of schizophrenia-like psychosis with younger age

  • f first marijuana use

Source: Arseneault et al BMJ, 2002

Study controlled for other mental illness and social background

slide-29
SLIDE 29

29

2.9 3.0 1.6 2.9 3.8 5.6 15.5 6.6 4.0 2.2 6.0 9.0 10.8 23.0 6.3 4.1 3.1 8.0 9.8 7.6 36.8

0.0 5.0 10.0 15.0 20.0 25.0 30.0 35.0 40.0

A l c

  • h
  • l

U s e D i s

  • r

d e r P r e s c r i p t i

  • n
  • p

i

  • i

d u s e … S e d a t i v e / t r a n q u i l i z e r u s e … S t i m u l a n t u s e d i s

  • r

d e r C

  • c

a i n e u s e d i s

  • r

d e r H e r

  • i

n u s e d i s

  • r

d e r E v e r i n j e c t i n g d r u g s

Increased Risk for Adverse Outcome

Increased Risk for Ever Using Marijuana (but no past year use) Compared to Never Using Marijuana Increased Risk for Past Year Marijuana Use Compared to Never Using Marijuana Increased Risk for Past Year Use of Marijuana 200 Days or More Compared to Never Using Marijuana

Drug Risks Associated with Marijuana Use Among U.S. Adults 18 and Older

slide-30
SLIDE 30

30

Mental Health and Social Risks of Marijuana Use Among U.S. Adults 18 and Older

Source: Jones CM Analysis of 2015-2016 NSDUH Public Use File Data

* ¥ ¥ ¥

1.6 1.4 1.1 2.5 1.2 2.0 1.5 1.2 2.1 1.2 2.2 1.7 1.4 2.4 1.3 0.0 0.5 1.0 1.5 2.0 2.5 3.0 Any mental illness Serious mental illness Unemployed Probation or parole Government assistance program

Increased Risk for Ever Using Marijuana (but no past year use) Compared to Never Using Marijuana Increased Risk for Past Year Marijuana Use Compared to Never Using Marijuana Increased Risk for Past Year Use of Marijuana 200 Days or More Compared to Never Using Marijuana

*

Increased Risk for Adverse Outcome

*not statistically significant

slide-31
SLIDE 31

31

Risk for Adverse Outcome

FREQUENCY OF CANNABIS USE BEFORE AGE 17 YEARS AND ADVERSE OUTCOMES (30 YEARS AGE) (N=2500-3700)

Consistent and dose-response association were found between frequency

  • f adolescent cannabis use and adverse outcomes

Source: Silins E et al., The Lancet September 2014

0.0 2.0 4.0 6.0 8.0 10.0 12.0 14.0 16.0 18.0 20.0 Cannabis Dependence Other Illicit Drug Use Suicide Attempt Less than Monthly Monthly or More Weekly or More Daily 0.2 0.4 0.6 0.8 1 1.2 1.4 High School Completion Degee Attainment Welfare Dependence Less than Monthly Monthly or More Weekly or More Daily

Frequency of cannabis use linked to increased risk for cannabis dependence, other illicit drug use, and suicide attempt Frequency of cannabis use linked to decreased high school completion and degree attainment, and linked to increased risk of welfare dependence

slide-32
SLIDE 32

32

Is There Medical Use for Marijuana?

  • Recent FDA approval of cannabidiol:
  • Evidence for medical value of some components of marijuana:
  • CBD and seizure disorder (Dravet’s syndrome and Lennox-Gastaut syndrome)
  • THC products for wasting illnesses and appetite production
  • What about marijuana for chronic pain management?
  • Modest evidence to suggest that cannabinoids (THC, CBD, combined CBD/THC, not

marijuana):

  • May be beneficial for neuropathic or cancer pain (37% vs. 31% (placebo); 8 studies; did

not reach statistical significance)

  • May improve spasticity due to MS or paraplegia (did not reach statistical significance)

(Whiting PF et al., 2015, Khalsa J, et al. 2019)

  • Side effects prominent: sedation, confusion, dry mouth, fatigue, nausea/vomiting,

hallucinations

32

slide-33
SLIDE 33

33

Medications Development

  • Medications must have undergone substantial research to answer critical

questions before getting to market and widespread use in humans:

  • Isolation of single components; manufacturing processes
  • Delivery mechanism
  • Pharmacokinetics/pharmacodynamics
  • Dose-response relationships (e.g.: doubling a dose may or may not

double the effect)

  • Therapeutic range
  • Adverse events: what are they and how best to avoid/address should

they occur?

  • Marijuana could not meet these requirements because it has so many

components (525 chemical constituents, 104 cannabinoids)

slide-34
SLIDE 34

34

Adverse outcomes linked to marijuana use by youth:

  • Poor school performance and increased drop out rates
  • Chronic use in adolescence has been linked to decline

in IQ that may not recover with cessation (Meier et al. 2012)

  • Marijuana use in adolescence is associated with an

increased risk for later psychotic disorder in adulthood

(D’Souza, et al. 2016)

  • Marijuana use linked to earlier onset of psychosis in

youth known to be at risk for schizophrenia (McHugh, et al.

2017)

And One More Thing---Accumulating Data on Potential Adverse Impacts of Marijuana Use: Does This Look Like a Treatment for Opioid Use Disorder?

  • Significant numbers who try marijuana will

become addicted (Lopez-Quintero, et al. 2011)

  • Higher overall rates of car crashes in states

that have legalized (WAPO, June 2017)

  • Association of marijuana use with abuse of

prescription pain medications (Olfson et al. 2017) Marijuana and Pregnancy:

  • Fetal growth restriction
  • Stillbirth
  • Preterm birth
  • May cause problems

with neurological development Hyperactivity Poor cognitive function

(Metz TD and Stickrath EH, 2015)

slide-35
SLIDE 35

35

Where Do We Go From Here?

  • Government has a responsibility to inform Americans of the risks of marijuana use
  • People need to be able to make informed choices
  • States should consider short and long term issues related to marijuana:
  • Tax revenue
  • Societal costs
  • Costs to taxpayers for adverse health effects of marijuana use
  • Need for regulation
  • Stop legislating medical uses for which there is NO evidence

SAMHSA:

  • Continue NSDUH and DAWN data collection related to marijuana
  • Specific materials aimed at special pops re: pregnant women, youth
  • Assist in identification of hazardous use and use disorders with SBIRT
  • Fund prevention, treatment and recovery services in states/communities
  • Research on drug development for promising components
  • Provide educational materials for providers and for the public related to

marijuana risks

slide-36
SLIDE 36

36

36

Public Education Resources

slide-37
SLIDE 37

37

37

Public Education Resources

slide-38
SLIDE 38

38

SAMHSA’s mission is to reduce the impact of substance abuse and mental illness on America’s communities.

www.samhsa.gov

1-877-SAMHSA-7 (1-877-726-4727) ● 1-800-487-4889 (TDD)

Thank You

Findtreatment.samhsa.gov